**BREATHTEC BIOMEDICAL INC.**Suite 890, 789 West Pender Street  
Vancouver, British Columbia, Canada V6C 1H2

## Breathtec Biomedical to Present at 2016 International Association of Breath Research

**--Company provides sponsorship support and delivers scientific presentation on topical issues at 2016 IABR Breath Summit in Zurich, Switzerland, September 14th-16th.**

VANCOUVER, BRITISH COLUMBIA – September 8, 2016 – [Breathtec BioMedical, Inc](http://breathtecbiomedical.com/). (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “**Company**” or “**Breathtec**”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases is pleased to announce that Chief Technology Officer Dr. Michael Costanzo will be making a presentation regarding the development of the Company’s technology at the [2016 IABR Breath Summit](http://breathsummit.com/) scheduled for September 14 to 16 in Zurich, Switzerland.

Dr. Costanzo will be giving an oral presentation entitled “Developing a Point-of-Care Device for Breath Analysis Utilizing FAIMS and FAIMS/MS” at the event hosted by the International Association of Breath Research (IABR). The presentation provides context for the continued development of a breath analyzer which offers rapid measurement, high sensitivity and specificity in a form factor targeting low cost manufacturing for a broad commercial market.

Medical advancements have progressed rapidly over the past decade and scientific methodologies have been established that identify specific chemical compounds (“disease biomarkers”) as consistently present in the breath or bodily fluids of people suffering from various medical conditions, such as TB, pneumonia, cancers or diabetes. Low cost Point-of-Care tests that can recognize these biomarkers *in vivo*, or in the native breath sample, would allow a new way of diagnosing these diseases at an early stage and avoid the need for costly (and often lengthy) invasive medical procedures. Breathtec Biomedical, in partnership with the Yost Group at the University of Florida have been developing a mobile breath testing device that will provide an economical, accurate, and portable solution. Breathtec aims to start initial trial testing of its portable FAIMS device late 2016 - early 2017 in partnership with Canadian and US medical practitioners.

“Since the advent of modern breath analysis techniques in the early 1970’s, many advancements have been made and our company is aiming to leverage a new direction that delivers tangible results.” Notes Dr. Costanzo, who continues, “Our approach at Breathtec could shift the paradigm of biomedical diagnostic screening, and this particular conference is very important to our efforts. I am therefore personally delighted to provide our corporate support to the association as a sponsor of the event. It is through collaborative events such as this that ideas become tangible solutions.”

**About the IABR**

The International Association for Breath Research (IABR) was founded in May 2005 in Vienna. The Scientific Advisory Board consists of leading researchers in this field. Its aims to promote scientific research and development in the field of breath analysis. This includes the development of analytical techniques, sampling procedures and standardization of measurements. IABR encourages the development of breath analysis for clinical diagnosis and therapeutic monitoring and supports researchers in the field of breath analysis and encourages scientific exchanges and collaboration between different research groups.

Find out more at <http://www.breathinternational.com> and it’s 2016 conference at <http://breathsummit.com/>.

**ON BEHALF OF THE BOARD**

"Guy LaTorre"  
CEO & Director

**For further information, please contact:**

Kal Malhi

President and Director

[Breathtec BioMedical, Inc](http://breathtecbiomedical.com/)

or

Core Capital Partners   
Telephone: 604-566-9233  
Email: [investors@ccpartnersinc.com](mailto:investors@ccpartnersinc.com)

*CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release*.

*This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*